Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19
a study on COVID-19
Summary
- Eligibility
- for people ages 18-80 (full criteria)
- Location
- at Fresno, California
- Dates
- study startedestimated completion
Description
Summary
This study is designed rapidly assess safety and preliminary efficacy in hospitalized patients with COVID-19 respiratory distress to provide clinical guidance for possible wider use in treating patients in this pandemic environment. This data will be used for FDA IND filings and pursuit of a BLA.
Official Title
COVID-19 Stem Cell Therapy: A Phase I Study of Intravenous Administration of Allogeneic Adipose Stem Cells
Details
This study is single arm, non-randomized Phase 1 study of the safety and preliminary efficacy of PSC-04, an adipose-derived allogeneic mesenchymal stem cell. The outcome data will be compared to contemporaneous non-enrolled patients at the same clinical site(s) as the enrolled patients. Study Objectives: Primary: To evaluate the safety of intravenous infusion of allogeneic adipose stem cells in patients with COVID-19 disease and respiratory distress. Secondary: To evaluate a set of secondary safety and efficacy outcome variables to give guidance in assessing the risk/benefit ratio in patients with COVID-19 respiratory distress.
Keywords
Covid19 adipose stem cell COVID-19 pneumonia PSC-04
Eligibility
You can join if…
Open to people ages 18-80
- Admitted to hospital as in-patient (ward or ICU)
- Respiratory distress - respiratory rate ≥ 30/minute (or PaO2:FiO2 <300)
- Bilateral lung infiltrates (CT or frontal X-ray)
- Supplemental oxygen started but NOT intubated or ventilated
- COVID-19 (SARS-CoV-2) antigen test positive (FDA-approved test);
- CDC confirmation not necessary
- Time from Enrollment to treatment must be less than 24 hours
- Age: 18-80 years
- Gender: any
- Suitability for cellular therapy: In the opinion of the Investigator or the Sponsor the patient is suitable for cellular therapy
- Cognitive function: Able to understand and willing to sign informed consent form or legally authorized representative or surrogate
You CAN'T join if...
- Intubation / ventilation
- Current therapy is working, and patient is clinically improving
- Disease Conditions: Heart failure severe (NY Heart Association Classification IV); Clinical evidence of left heart failure or volume overload as a primary explanation for the bilateral pulmonary infiltrates; Any disease or condition other than current respiratory COVID-19 disease for which 6-month mortality is estimated to be greater than 50%; Moderate to severe liver failure; Severe chronic respiratory disease or the use of home oxygen use prior to this current illness; Currently receiving extracorporeal life support (ECLS/ECMO)
- Past Disease Conditions: Any history of malignancy within the last 2 years (except for patients in remission or cured of the malignancy); Lung transplant patient or lobectomy; Deep venous thrombosis or pulmonary embolism within past 3 months; History of splenectomy
- Other Experimental Conditions: Currently enrolled or treated in last 60 days in another clinical study
- Consent Issues: Do not resuscitate (DNR) order in place; Not willing to follow lung protective ventilation strategy, if needed
- Concurrent disease or circumstances that Investigator or Sponsor judges to be an unacceptable risk to patient health or a confounding variable to assessment or problem in completion of trial.
Location
- Fresno Community Hospital
accepting new patients
Fresno California 93710 United States
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Sorrento Therapeutics, Inc.
- ID
- NCT04486001
- Phase
- Phase 1
- Study Type
- Interventional
- Last Updated
Frequently Asked Questions
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
Thank you!
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT04486001.